Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis
- 31 July 2001
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 15 (3) , 469-481
- https://doi.org/10.1053/berh.2001.0161
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Management of corticosteroid-induced osteoporosisSeminars in Arthritis and Rheumatism, 2000
- Bisphosphonates: Pharmacology, Mechanisms of Action and Clinical UsesOsteoporosis International, 1999
- Bisphosphonates: Mechanisms of ActionEndocrine Reviews, 1998
- Use of cyclical etidronate and prevention of non-vertebral fractures.Rheumatology, 1998
- Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced OsteoporosisNew England Journal of Medicine, 1997
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized studyThe American Journal of Medicine, 1995
- Intermittent Cyclical Etidronate Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990